СТВОЛОВЫЕ КЛЕТКИ ПРИ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗАХ
Ключові слова:
гострі мієлоїдні лейкози, лейкемічні стовбурові клітини, мікроРНК.Анотація
Резюме. В огляді проаналізовано сучасні уявлення про лейкемічні стовбурові клітини (ЛСК) при гострих мі-єлоїдних лейкозах. Існування ЛСК було вперше вста-новлено в 1997 р. ЛСК виникають із гемопоетичних стовбурових клітин або комітованих гемопоетичних клітин-попередників. У процесі злоякісної трансфор-мації вони набувають здатності до самопідтримки, проліферації і диференціації внаслідок генетичних та епігенетичних змін і клональної диверсифікації. У ре-гуляції ЛСК істотне значення має взаємодія з мікро-оточенням, сигнальні шляхи, мікроРНК. Подальші зу-силля повин ні бути спрямовані на створення методів терапії з метою елімінації ЛСК.
Посилання
Fialkow P. Acute nonlymphoblastic leukemia: heterogene-ity of stem cell origin. Blood 1981; 57: 1068–73.2. Dick JE. Normal and leukemic stem cells assayed in SCID mice. Semin Immunol 1996; 8: 197–206.3. Passegue E, Jamleson CHM, Ailles LE, Weissman IL. Nor-mal and leukemic hematopoiesis: are leukemias a stem cell disor-ders or a reaquisition of stem cell characteristics. Proc Natl Acad Sci USA 2003; 100: 11842–49.4. Huntly BJD, Gilliland DG. Leukemia stem cells and the evolution of cancer stem cell research. Nat Rev Cancer 2005; 5: 311–20.5. Reya T, Morrison S, Clarke M, Weissman I. Stem cells, can-cer and cancer stem cells. Nature 2011; 414: 105–11.6. Bonnet D, Dick JE. Human acute myeloid leukemia is or-ganised as a hierarchy that originate from primitive hematopoiet-ic cell. Nat Med 1997; 3 (7): 730–37.7. Wang JCY, Dick JE. Cancer stem cells. In: Devita, Hell-man and Rosenberg’s Cancer: Principles and Practice of Oncol-ogy, 8th ed. N.Y.: Lippincot Williams and Wilkins, 2008: 136–46.8. Surry JE, Murphy K, Perry R, et al.Human acute myeloge-nous leukemia stem cells are rare and heterogenous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest 2011; 121(1): 384–95.9. Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 2017; 129 (12): 1577–85.10. Dick JE. Acute myeloid leukaemia stem cells. Ann NY Acad Sci 2005; 1044: 1–5.11. Pabst C, Bergeron A, Lavallec VP, et al.GPR56 identifies primary human acute myeloid leukemia cells was high repopulat-ing potential in vivo. Blood 2016; 127 (16): 2018–27.12. Iwasaki M, Liedtke M, Gentles AJ, Cleary ML. CD93 marks a non-quiescent human leukemia stem cell population and is re-quired for development of MLL-rearrangement acute myeloid leu-kemia. Cell Stem Cells 2015; 17 (4): 412–21.13. Eppert K, Takenaka K, Lechman ER, et al.Stem cell gene expression programs influence clinical outcome in human leuke-mia. Nat Med 2011; 17 (9): 1086–93.14. Taussig DC, Vargaftig J, Miraki-Moud F, et al.Leukemia-initiating cells from some acute myeloid leukemia patients with mu-tated nucleophosmin reside in the CD34(–)fraction. Blood 2010; 115 (10): 1976–84.15. Quek L, Otto GM, Garnett C, et al.Genetically distinct leukemic stem cells in human CD34– acute myeloid leukemia are arrested at a hematopoietic precursor-like stage. J Exp Med 2016; 213 (8): 1513–35.16. Miyamoto T, Weissman IL, Akashi K. AML1/ETO expres-sion nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97 (13): 7521–26.17. Guibal FC, Alterich-Jorda M, Hirai H, et al.Identification of a myeloid comitted progenitor as the cancer-initiating in acute promyelocytic leukemia. Blood 2009; 114 (27): 5415–25.18. Чертков ИЛ, Гуревич ОА. Стволовая кроветворная клетка и ее микроокружение. М: Медицина, 1984. 240 с.19. Colmone A, Amorim M, Pontier AL, et al.Leukemic cells create bone marrow niches that disrupt the behavior of normal he-matopoietic progenitor cells. Science 2008; 322: 1861–65.20. Konopleva MY, Jordan CT. Leukemia stem cells and mi-croenvironment: biology and therapeutic targeting. J Clin Oncol 2011; 29: 591–99.21. Spoo AC, Lubbert M, Wierda WC, Burger JA.CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786–91.22. Jacamo R, Chen Y, Wang Z, et al.Reciprocal leukemia-stro-ma VCAM-1/VLA-4 dependent activation of NF-kappaB medi-ates chemoresistance. Blood 2014; 123: 2691–702.23. Mardis ER, Ding L, Dooling DJ, et al.Recurring muta-tions found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–66.24. Greif PA, Eck SH, Konstandin NP, et al.Identification of recurring tumor-specific somatic mutations in acute my-eloid leukemia by transcriptome sequencing. Leukemia 2011; 25: 821–27.25. Cancer Genome Atlas Research. Genomic and epigenom-ic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–74.26. Kreso A, Dick JE. Evolution of the cancer stem cell mod-el. Cell Stem Cell 2014; 14 (3): 275–91.27. Wang K, Sanchez-Martin M, Wang X, et al.Patient-de-rived xenotransplantants can recapitulate the genetic driven land-scape of acute leukemia. Leukemia 2017; 31 (1): 151–58.28. Wang X, Huang Sh, Chen J-L. Understanding of leuke-mic stem cells and their clinical implications. Mol Cancer 2017; 16 (2): 1–27.29. Saito Y, Uchida N, Tanaka S, et al.Induction of cell cy-cle entry eliminates human leukemia stem cells in mouse model of AML. Nat Biotechnol 2010; 28 (3): 275–80.30. Jin L, Lee EM, Ramshaw HS, et al.Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, elimi-nates human acute myeloid leukemia stem cells. Cell Stem Cell 2009; 5 (1): 31–42.31. Schepers K, Pietras EM, Reynaud D, et al.Myelopro-liferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemia niche. Cell Stem Cell 2013; 13: 285–89.32. Wang Y, Krivtsov AV, Sinha AU, et al.The Want/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650–53.33. Siapati EK, Papadaki M, Kozaou Z, et al.Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol 2011; 152: 164–74.
Zhao C, Chen A, Jamieson CH, et al.Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leuke-mia. Nature 2009; 458: 776–79.35. Reya T, Duncan AW, Ailles L, et al.A role for Wnt signal-ling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 404–14.36. Cobas M, Wilson A, Ernst B, et al.Beta-catenin in dis-pensable for hematopoiesis and lymphopoiesis. J Exp Med 2004; 199: 211–13.37. Duchartre Y, Kim YM, Kahn M. The Wnt signalling path-way in cancer. Crit Rev Oncol Hematol 2016; 99: 141–49.38. Griffiths EA, Gore SD, Hooker C, et al.Acute myeloid leu-kemia is characterized by Wnt pathway inhibitor promotor hyper-methylation. Leuk Lymphoma 2010; 51: 1711–19.39. Guzman ML, Rossi RM, Karnischky L, et al.The sesqui-terpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163–69.40. Costello RT, Mallet F, Gaugler B, et al.Human acute my-eloid leukemia CD34+/CD38– progenitor cells have decreased sen-sitivity to chemotherapy and FAS-induced apoptosis, reduced im-munogenicity, and impaired dendritic cell transformation capac-ities. Cancer Res 2000; 60: 4403–11.41. Аушев ВН. МикроРНК: малые молекулы с большим значением. Онкогематология 2015; 8 (1): 1–12.42. Liao Q, Wang B, Li X, Jiang G. miRNAs in acute myeloid leukemia. Oncotarget 2017; 8 (2): 3666–82.43. Weiss CN, Ito K. A macro view of microRNAs: the disco-very of microRNAs and their role in hematopoiesis and hemato-logic disease. Int Rew Cell Mol Biol 2017; 334: 99–175.44. Bousquet M, Quelen C, Rosati R, et al.Myeloid cell differ-entiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid keukemia with the t(11;14)(p21;q23) translocation. J Exp Med 2008; 205 (11): 2499–506.45. Lechman ER, Gentner B, Ng SWK, et al.MiR-126 regu-lates distinct self-renewal outcomes in normal and malignant he-matopoietic stem cells. Cancer Cell 2016; 29 (4): 214–28.46. Dorrance AM, Neviant P, Ferenchak GJ, et al.Targeting leukemia stem cells in vivo with antagomiR–126 nanoparticles in acute myeloid leukemia. Leukemia 2015; 29 (11): 2143–53.47. Lechman ER, Gentner B, van Galen P, et al.Attentiation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cells 2012; 11 (6): 799–811.48. Wang XS, Gong JN, Yu J, et al.MicroRNA-29a and mi-croRNA-142-3p are regulators of myeloid differentiation and acute myeloid keukemia. Blood 2012; 119 (21): 4999–5004.49. Dahhaus M, Rolf C, Ruck C, et al.Expression and prog-nostic significance of hsa-miR-142-3p in acute leukemias. Neo-plasma 2013; 60 (4): 432–38.50. Gong JN, Yu J, Lin HS, et al.The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ 2014; 21 (1): 100–12.51. Han YC, Park CY, Bhagat G, et al.MicroRNA-29a induc-es aberrant self-renewal capacity in hematopoietic progenitors, bi-ased myeloid development and acute myeloid leukemia. J Exp Med 2010; 207 (3): 475–89.52. Khalay M, Tavankoli M, Stranahan AW, Park CY.Pathogenic microRNA’s in myeloid malignancies. Front Genet 2014; 5: 1–18.53. Wong P, Iwasaki M, Somervaille TC, et al.The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell po-tential by modulating p21 expression. Cancer Res 2010; 70 (9): 3833–42.54. Velu CS, Chaubey A, Phelan JD, et al.Theraupetic antago-nists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest 2014; 124 (1): 222–36.55. Wang Y, Cheng Q, Liu J, Dong M.Leukemia stem cell-re-leased microvesicles promote the survival and migration of myeloid leukemia cells and these effects can be inhibited by microRNA-34a overexpression. Stem Cell Intern 2016; 9: 313–25
